Michael Lauseker, Markus Pfirrmann, Verena S. Hoffmann, Joerg Hasford. Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed” Haematologica 2011;96(12):1779–82. haematol [Internet]. 2012May3 [cited 2024Apr.26];97(5):e14-e15. Available from: https://haematologica.org/article/view/6309